CoChat
Sign Up
Cited by 517Atherosclerosis and Cardiovascular DiseasesCholesterol and Lipid MetabolismLipoproteins and Cardiovascular Health

CD36, a scavenger receptor implicated in atherosclerosis

Open access
Park, Young Mi·2014·Experimental & Molecular Medicine
DOI 10.1038/emm.2014.38PMC PMC4081553
Open this paper in CoChat — free accountOpen PDF

Abstract

CD36 is a membrane glycoprotein that is present on various types of cells, including monocytes, macrophages, microvascular endothelial cells, adipocytes and platelets. Macrophage CD36 participates in atherosclerotic arterial lesion formation through its interaction with oxidized low-density lipoprotein (oxLDL), which triggers signaling cascades for inflammatory responses. CD36 functions in oxLDL uptake and foam cell formation, which is the initial critical stage of atherosclerosis. In addition, oxLDL via CD36 inhibits macrophage migration, which may be a macrophage-trapping mechanism in atherosclerotic lesions. The role of CD36 was examined in in vitro studies and in vivo experiments, which investigated various functions of CD36 in atherosclerosis and revealed that CD36 deficiency reduces atherosclerotic lesion formation. Platelet CD36 also promotes atherosclerotic inflammatory processes and is involved in thrombus formation after atherosclerotic plaque rupture. Because CD36 is an essential component of atherosclerosis, defining the function of CD36 and its corresponding signaling pathway may lead to a new treatment strategy for atherosclerosis. CD36, a protein found on the surface of various immune cells and blood vessel cells, is a key component of atherosclerosis. Young Mi Park from the Ewha Womans University School of Medicine in Seoul, South Korea, reviews how the CD36 protein on macrophages binds to a form of ‘bad’ cholesterol called oxidized low-density lipoprotein. This binding triggers a series of reactions that leads to inflammation and the formation of foam cells, fat-laden immune cells involved in plaque-build up on the inner lining of blood vessels. CD36 on platelets also promotes inflammatory responses involved in blood clots after plaques rupture. Park argues that a better understanding of CD36 and its functions could lead to new treatments for atherosclerosis, a condition commonly associated with an increased risk of heart attack and stroke.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/emm.2014.38

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Expression of CD36 on macrophages and platelets promotes signaling cascades of inflammation which eventually participates in atherosclerotic arterial lesion formation and thrombus formation.

    “The expression of CD36 on macrophages and platelets also promotes signaling cascades of inflammation which eventually participates in atherosclerotic arterial lesion formation and thrombus formation [144].”

    From Insights of Endocytosis Signaling in Health and Disease (2023) · cites this paper as [144]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 79

  1. Febbraio M Hajjar DP Silverstein RL CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation and lipid metabolism J Clin Inv 2001 108 785 791 PMC200943 11560944
  2. Calvo D Dopazo J Vega MA The CD36, CLA-1 (CD36L1), and LIMPII (CD36L2) gene family: cellular distribution, chromosomal location, and genetic evolution Genomics 1995 25 100 106 7539776
  3. Hoosdally SJ Andress EJ Wooding C Marin CA Linton KJ The human scavenger receptor CD36; glycosylation status and its role in trafficking and function J Biol Chem 2009 284 16277 16288 19369259 PMC2713513
  4. Navazo P Daviet L Ninio E McGregor JL Identification on human CD36 of a domain (155-183) implicated in binding oxidized low-density lipoproteins (Ox-LDL) Arterioscler Thromb Vasc Biol 1996 16 1033 1039 8696943
  5. Dawson DW Pearce SFA Zhong R Silverstein RL Frazier WA Bouck NP CD36 mediates the inhibitory effects of thrombospondin-1 on endothelial cells J Cell Biol 1997 138 707 717 9245797 PMC2141641
  6. Abumrad NA el-Maghrabi MA Amri EZ Lopez E Grimaldi PA Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during peadipocyte differentiation. Homology with human CD36 J Biol Chem 1993 268 17665 17668 7688729
  7. Hansson GK Immune mechanism in atherosclerosis Arterioscler Thromb Vasc Biol 2001 20 1876 1890 11742859
  8. Greenberg ME Li XM Gugiu BG Gu X Qin J Salomon RG The lipid whisker model of the structure of oxidized cell membranes J Biol Chem 2008 283 2385 2396 18045864
  9. Leitinger N Oxidized phospholipids as modulators of inflammation in atherosclerosis Curr Opin Lipidol 2003 14 421 430 14501580
  10. Podrez EA Febbraio M Sheibani N Schmitt D Silverstein RL Hajjar DP The macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species J Clin Invest 2000 105 1095 1108 10772654 PMC300829
  11. Boullier A Gillotte KL Hörkkö S Green SR Friedman P Dennis EA The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein J Biol Chem 2000 275 9163 9169 10734051
  12. Bird DA Gillotte KL Hörkkö S Friedman P Dennis EA Witztum JL Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: Implications with respect to macrophage recognition of apoptotic cells Proc Natl Acad Sci USA 1999 96 6347 6352 10339590 PMC26884
  13. Podrez EA Poliakov E Shen Z Zhang R Deng Y Sun M A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions J Biol Chem 2002 277 38517 38523 12145296
  14. Libby P Inflammation in atherosclerosis Nature 2002 407 233 241 12490960
  15. Endeman G Stanton LW Madden KS Bryant CM White RT Protter AA CD36 is a receptor for oxidized low density lipoprotein J Biol Chem 1993 268 11811 11816 7685021
  16. Nagy L Tontonoz P Alvarez JG Chen H Evans RM Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-γ Cell 1998 93 229 240 9568715
  17. Tontonoz P Nagy L Alvarez JG Thomazy VA Evans RM PPAR-γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL Cell 1998 93 241 252 9568716
  18. Carr AC McCall MR Frei B Oxidation of LDL by myeloperoxidase and reactive oxygen species; reaction pathways and antioxidant protection Arterioscler Thromb Vasc Biol 2000 20 1716 1723 10894808
  19. Jiang Y Wang M Huang K Zhang Z Shao N Zhang Y Oxidized low-density lipoprotein induces secretion of interleukin-1β by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation Biochem Biophys Res Commun 2012 425 121 126 22796220
  20. Febbraio M Podrez EA Smith JD Hajjar DP Hazen SL Hoff HF Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice J Clin Invest 2000 105 1049 1056 10772649 PMC300837
  21. Guy E Kuchibhotla S Silverstein R Febbraio M Continued inhibition of atherosclerotic lesion development in long term western diet fed CD360/ apoE0 mice Atherosclerosis 2007 192 123 130 16919281
  22. Kuchibhotla S Vanegas D Kennedy DJ Guy E Nimako G Morton RE Absence of CD36 protects against atherosclerosis in ApoE knock-out mice with no additional protection provided by absence of scavenger receptor A I/II Cardiovasc Res 2008 78 185 196 18065445 PMC2810680
  23. Febbraio M Guy E Silverstein RL Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis Arterioscler Thromb Vasc Biol 2004 24 2333 2338 15486305
  24. Marleau S Harb D Bujold K Avallone R Iken K Wang Y EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions FASEB J 2005 19 1869 1871 16123174
  25. Moore KJ Kunjathoor VV Koehn SL Manning JJ Tseng AA Silver JM Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice J Clin Invest 2005 115 2192 2201 16075060 PMC1180534
  26. Witztum JL You are right, too J Clin Invest 2005 115 2072 2075 16075051 PMC1180570
  27. Collot-Teixeira S Martin J McDeromott-Roe C Poston R McGregor JL CD36 and macrophages in atherosclerosis Cardiovasc Res 2007 75 468 477 17442283
  28. Kennedy DJ Kuchibhotla SD Guy E Park YM Nimako G Vanegas D Dietary cholesterol plays a role in CD36-mediated atherogenesis in LDLR-knockout mice Arterioscler Thromb Vasc Biol 2009 29 1481 1487 19608973 PMC2756023
  29. Manning-Tobin JJ Moore KJ Seimon TA Bell SA Sharuk M Alvarez-Leite JI Freeman M.W. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice Arterioscler Thromb Vasc Biol 2009 29 19 26 18948635 PMC2666043
  30. Chen K Febbraio M Li W Silverstein RL A specific CD36-dependent signaling pathway is required for platelet activation by oxLDL Circ Res 2008 102 1512 1519 18497330 PMC2749986
  31. Dawson DW Pearce SF Zhong R Silverstein RL Frazier WA Bouck NP CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells J Cell Biol 1997 138 707 717 9245797 PMC2141641
  32. Rahaman SO Lennon DJ Febbraio M Podrez EA Hazen SL Silverstein RL A CD36-dependent signaling cascade is necessary for macrophage foam cell formation Cell Metab 2006 4 211 221 16950138 PMC1855263
  33. Rahaman SO Zhou G Silverstein RL Vav protein guanine nucleotide exchange factor regulates CD36 protein-mediated macrophage foam cell formation via calcium and dynamin-dependent processes J Biol Chem 2011 286 36011 36019 21865158 PMC3195569
  34. Rahaman SO Li W Silverstein RL Vav guanine nucleotide exchange factors regulate atherosclerotic lesion development in mice Arterioscler Thromb Vasc Biol 2013 33 2053 2057 23825362 PMC3864095
  35. Xia F Li R Wang C Yang S Tian L Dong H IRGM1 regulates oxidized LDL uptake by macrophage via actin-dependent receptor internalization during atherosclerosis Sci Rep 2013 3 1867 23689639 PMC3659323
  36. Zhao M Liu Y Wang X New L Han J Brunk UT Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL APMIS 2002 110 458 468 12193207
  37. Yamashita S Hirano K Kuwasako T Janabi M Toyama Y Ishigami M Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis: insights from CD36-deficient patients Mol Cell Biochem 2007 299 19 22 16670819
  38. Miao WM Vasile E Lane WS Lawler J CD36 associates with CD9 and integrins on human blood platelets Blood 2001 97 1689 1696 11238109
  39. Akira S Toll-like receptor signaling J Biol Chem 2003 278 38105 38108 12893815
  40. Hashimoto M Tawaratsumida K Kariya H Kiyohara A Suda Y Krikae F Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus J Immunol 2006 177 3162 3169 16920954
  41. Triantafilou M Gamper G Haston RM Mouratis MA Morath S Hartung T Membrane sorting of toll-like receptor (TLR)-2/6 and TLR 2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting J Biol Chem 2006 281 31002 31011 16880211
  42. Erdman LK Cosio G Helmers AJ Gowda DC Grinstein S Kain KC CD36 and TLR interactions in inflammation and phagocytosis: implications for malaria J Immuol 2009 183 2452 2459 PMC2853812 19864601
  43. Sheedy FJ Grebe A Rayner KJ Kalantari P Ramkhelawon B Carpenter SB CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation Nat Immunol 2013 14 812 820 23812099 PMC3720827
  44. Rathinam VA Vanaja SK Fitzgerald KA Regulation of inflammasome signaling Nat Immunol 2012 13 333 342 22430786 PMC3523703
  45. Rios FJ Ferracini M Pecenin M Koga MM Wang Y Ketelhuth DF Uptake of oxLDL and IL-10 production by macrophages requires PAFR and CD36 recruitment into the same lipid rafts PLoS ONE 2013 8 e76893 24130805 PMC3793910
  46. Heit B Kim H Cosío G Castaño D Collins R Lowell CA Multimolecular signaling complexes enable Syk-mediated signaling of CD36 internalization Dev Cell 2013 24 372 383 23395392 PMC3586299
  47. Reis ED Lie J Fayad ZA Rong JX Hansoty D Aguinaldo JG Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model Vasc Surgery 2001 34 541 547 11533609
  48. Chereshnev I Trogan E Omerhodzic S Itskovich V Aguinaldo JG Fayad ZA Mouse model of heterotopic aortic arch transplantation J Surg Res 2003 111 171 176 12850459
  49. Llodra J Angeli V Liu J Trogan E Fisher EA Randolph GJ Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques Proc Natl Acad Sci USA 2004 101 11779 11784 15280540 PMC511052
  50. Quinn MT Parthasarathy S Fong LG Steinberg D Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophagesduring atherogenesis Proc Natl Acad Sci USA 1987 84 2995 2998 3472245 PMC304787
  51. Park YM Febbraio M Silverstein RL CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima J Clin Invest 2009 119 136 145 19065049 PMC2613464
  52. Park YM Drazba JA Vasanji A Egelhoff T Febbraio M Silverstein RL Oxidized LDL/CD36 interaction induces loss of cell polarity and inhibits macrophage locomotion Mol Cell Biol 2012 23 3057 3068 PMC3418302 22718904
  53. Fuentes QE Fuentes QF Andrés V Pello OM de Mora JF Palomo GI Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis Platelets 2013 24 255 262 22671308
  54. Chen K Li W Major J Rahaman SO Febbraio M Silverstein RL Vav guanine nucleotide exchange factors link hyperlipidemia and a prothrombotic state Blood 2011 117 5744 5750 21427288 PMC3110031
  55. Zimman A Titz B Komisopoulou E Biswas S Graeber TG Podrez EA Phosphoproteomic analysis of platelets activated by pro-thrombotic oxidized phospholipids and thrombin PLoS ONE 2014 9 e84488 24400094 PMC3882224
  56. Eitzman DT Westrick RJ Xu Z Tyson J Ginsburg D Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice Arterioscler Thromb Vasc Biol 2000 20 1831 1834 10894825
  57. Ghosh A Li W Febbraio M Espinola RG McCrae KR Cockrell E Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice J Clin Invest 2008 118 1934 1943 18431509 PMC2323190
  58. Zhu W Li W Silverstein RL Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36 Blood 2012 119 6136 6144 22431576 PMC3383021
  59. Siegel-Axel D Daub K Seizer P Lindemann S Gawaz M Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis Cardiovasc Res 2008 78 8 17 18218686
  60. Daub K Seizer P Stellos K Krämer BF Bigalke B Schaller M Oxidized LDL-activated platelets induce vascular inflammation Semin Thromb Hemost 2010 36 146 156 20414829
  61. Curtiss LK Black AS Takagi Y Plow EF New mechanism for foam cell generation in atherosclerotic lesions J Clin Invest 1987 80 367 373 2956278 PMC442246
  62. Badrnya S Schrottmaier WC Kral JB Yaiw KC Volf I Schabbauer G Platelets mediate oxidized low-density lipoprotein-induced monolayer extravasation and foam cell formation Arterioscler Thromb Vasc Biol 2013 34 571 580 24371083
  63. Lipsky RH Ikeda H Medved ES A dinucleotide repeat in the thrid intron of CD36 Hum Mol Gent 1994 3 217 7512858
  64. Yamamoto N Akamatsu N Sakuraba H Yamazaki H Tanoue K Platelet glycoprotein IV(CD36) deficiency is associated with the absence (type I) or the presence (type II) of glycoprotein IV on monocytes Blood 1994 83 392 397 7506948
  65. Kashiwagi H Tomiyama Y Kosugi S Shiraga M Lipsky RH Nagao N Family studies of type II CD36 deficient subjects: linkage of a CD36 allele to a platelet-specific mRNA expression defect(s) causing type II CD36 deficiency Thromb Haemost 1995 72 758 763 8585018
  66. Kashiwagi H Tomiyama Y Nozaki S Kiyoi T Tadokoro S Matsumoto K Analyses of genetic abnormalities in type I CD36 deficiency in Japan: idendification and cell biological characterization of two novel mutations that cause CD36 deficiency in man Hum Genet 2001 108 459 466 11499670
  67. Hanawa H Watanabe K Nakamura T Ogawa Y Toba K Fuse I Identification of cryptic splice site, exon skipping, and novel point mutations in type I CD36 deficiency J Med Genet 2002 39 286 291 11950861 PMC1735088
  68. Imai M Tanaka T Kintaka T Ikemoto T Shimizu A Kitaura Y Genomic heterogeneity of type II CD36 deficiency Clin Chim Acta 2002 321 97 106 12031598
  69. Kashiwagi H Tomiyama Y Kosugi S Shiraga M Lipsky RH Kanayama Y Identification of molecular defects in a subject with type I CD36 deficiency Blood 1994 83 3545 3552 7515716
  70. Fukuchi K Nozaki S Yoshizumi T Hasegawa S Uehara T Nakagawa T Enhanced myocardial glucose use in patients with a deficiency in long-chain fatty acid transport (CD36 deficiency) J Nucl Med 1999 40 239 243 10025829
  71. Hirano K Kuwasako T Nakagawa-Toyama Y Janabi M Yamashita S Matsuzawa Y Pathophysiology of human genetic CD36 deficiency Trends Cardiovasc Med 2003 13 136 141 12732446
  72. Yamamoto N Ikeda H Tandon NN Herman J Tomiyama Y Mitani T A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka-platelets lack detectable GPIV(CD36) Blood 1990 76 1698 1703 1699620
  73. Watanabe K Ohta Y Toba K Ogawa Y Hanawa H Hirokawa Y Myocardial CD36 expression and fatty acid accumulation in patients with type I and II CD36 deficiency Ann Nucl Med 1998 12 261 266 9839487
  74. Teraguchi M Ikemoto Y Unishi G Ohkohchi H Kobayashi Y Influence of CD36 deficiency on heart disease in children Circ J 2004 68 435 438 15118284
  75. Yanai H Chiba H Morimoto M Abe K Fujiwara H Fuda H Human CD36 deficiency is associated with elevation in low-density lipoprotein-cholesterol Am J Med Genet 2000 93 299 304 10946357
  76. Miyaoka K Kuwasako T Hirano K Nozaki S Yamashita S Matsuzawa Y CD36 deficiency associated with insulin resistance Lancet 2001 357 686 687 11247555
  77. Handberg A Levin K Højlund K Beck-Nielsen H Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance Circulation 2006 114 1169 1176 16952981
  78. Chmielewski M Bragfors-Helin AC Stenvinkel P Lindholm B Anderstam B Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients Clin Chim Acta 2010 411 2079 2082 20837002
  79. Handberg A Højlund K Gastaldelli A Flyvbjerg A Dekker JM Petrie J Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population J Intern Med 2012 271 294 304 21883535

Cited by

Sorted by citations

Authors
Park, Y. M.
Affiliations
Ewha Womans University (KR)
Corresponding author
Park, Young Mi
ORCID
Park, Young Mi
Venue
Experimental & Molecular Medicine
Publisher
Springer Science and Business Media LLC
Published
2014-06-06
Volume
46
Issue
6
Pages
e99-e99
ISSN
  • 1226-3613 (ISSN-L)
  • 2092-6413
DOI
10.1038/emm.2014.38
PMC
PMC4081553
OpenAlex
W2064760068
Cited by
517
References
4
Citations by year
2026: 32 · 2025: 42 · 2024: 53 · 2023: 53 · 2022: 53 · 2021: 56 · 2020: 52 · 2019: 40 · 2018: 33 · 2017: 32 · 2016: 41 · 2015: 24 · 2014: 6
FWCI
3.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Experimental & Molecular Medicine (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
  • National Research Foundation
  • Ministry of Science, ICT and Future Planning
  • National Research Foundation of Korea
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Keywords
CD36, scavenger receptors, atherosclerosis, oxidized LDL, foam cell formation, macrophages, platelets, macrophage migration, atherosclerotic plaque rupture, thrombus formation, inflammation, atherosclerotic lesion formation, CD36 deficiency
MeSH terms
Animals, Humans, Macrophages, CD36 Antigens, Atherosclerosis, Plaque, Atherosclerotic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review